Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF)'s (Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF)) CEO Danny Lee and CFO David Cocke present their latest results to Proactive London.
The firm say they are heading towards pre-pandemic activity levels backed by strong demand for its regenerative medicine products.
In 2021, the developer of biosurgery and orthopaedic technology posted double-digit growth as its revenues advanced 20% to US$19.7mln.
This resulted in a much-reduced operating loss, which fell to US$4.9mln in the 12 months ended 31 December from US$12.4mln previously.